Search research articles
Contact Us
Filters
Showing results (131-140 of 149) with videos related to
Page
of 15
Sort By:
Journal of the National Cancer Institute
|
March 7, 2015
The contributions of breast density and common genetic variation to breast cancer risk
Celine M Vachon, V Shane Pankratz, Christopher G Scott, et al.
Geburtshilfe Und Frauenheilkunde
|
November 5, 2019
Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018)
Hans-Georg Schnürch, Sven Ackermann, Celine D Alt-Radtke, et al.
BMC Cancer
|
October 16, 2024
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
Philipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 8, 2025
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer
Laura L Michel, Philipp Ziegler, Philipp Kreis, et al.
Geburtshilfe Und Frauenheilkunde
|
May 31, 2024
CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current Programs
Andreas Schneeweiss, Sara Y Brucker, Hanna Huebner, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 26, 2024
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole
Peter A Fasching, Carolin C Hack, Naiba Nabieva, et al.
Geburtshilfe Und Frauenheilkunde
|
February 12, 2024
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study
Carolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
Geburtshilfe Und Frauenheilkunde
|
April 19, 2021
Diagnosis and Treatment of Endometriosis. Guideline of the DGGG, SGGG and OEGGG (S2k Level, AWMF Registry Number 015/045, August 2020)
Stefanie Burghaus, Sebastian D Schäfer, Matthias W Beckmann, et al.
International Journal of Cancer
|
July 11, 2025
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial
Milena Beierlein, Lothar Häberle, Naiba Nabieva, et al.
International Journal of Cancer
|
March 23, 2019
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients
Naiba Nabieva, Lothar Häberle, Sara Y Brucker, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 149) with videos related to
Sort By:
Page
of 15
Journal of the National Cancer Institute
|
March 7, 2015
The contributions of breast density and common genetic variation to breast cancer risk
Celine M Vachon, V Shane Pankratz, Christopher G Scott, et al.
Geburtshilfe Und Frauenheilkunde
|
November 5, 2019
Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018)
Hans-Georg Schnürch, Sven Ackermann, Celine D Alt-Radtke, et al.
BMC Cancer
|
October 16, 2024
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
Philipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 8, 2025
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer
Laura L Michel, Philipp Ziegler, Philipp Kreis, et al.
Geburtshilfe Und Frauenheilkunde
|
May 31, 2024
CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current Programs
Andreas Schneeweiss, Sara Y Brucker, Hanna Huebner, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 26, 2024
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole
Peter A Fasching, Carolin C Hack, Naiba Nabieva, et al.
Geburtshilfe Und Frauenheilkunde
|
February 12, 2024
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study
Carolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
Geburtshilfe Und Frauenheilkunde
|
April 19, 2021
Diagnosis and Treatment of Endometriosis. Guideline of the DGGG, SGGG and OEGGG (S2k Level, AWMF Registry Number 015/045, August 2020)
Stefanie Burghaus, Sebastian D Schäfer, Matthias W Beckmann, et al.
International Journal of Cancer
|
July 11, 2025
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial
Milena Beierlein, Lothar Häberle, Naiba Nabieva, et al.
International Journal of Cancer
|
March 23, 2019
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients
Naiba Nabieva, Lothar Häberle, Sara Y Brucker, et al.
Page
of 15